Actively Recruiting
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2024-07-05
40
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate the efficacy and safety of TACE combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.
CONDITIONS
Official Title
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of hepatocellular carcinoma by histology, cytology, or clinical criteria
- Signed informed consent
- Age 18 years or older
- Eligible for TACE treatment
- ECOG physical condition score of 0 or 1
- No prior systemic therapy for hepatocellular carcinoma, especially immunotherapy
- At least one measurable intrahepatic lesion suitable for repeated evaluation according to mRECIST criteria
You will not qualify if you...
- History of kidney disease or nephrotic syndrome
- Evidence of extrahepatic spread
- Significant cardiovascular diseases, including unstable angina, grade 2 or higher congestive heart failure, or poorly controlled arrhythmia
- Any contraindication to TACE as determined by investigators
- Known genetic bleeding or thrombosis disorders or evidence of bleeding tendency
- Previous immunotherapy with anti PD-1, anti PD-L1, or anti CTLA-4
- Prior hepatic artery infusion chemotherapy, chemoembolization, embolization, or radiation embolization
- Previous systemic anti-cancer treatment for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or liver metastasis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Actively Recruiting
Research Team
H
Haipeng Yu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here